🇺🇸 FDA
Patent

US 11582956

Recombinant adenovirus-based interferon biotherapeutics in swine

granted A61KA61K48/005

Quick answer

US patent 11582956 (Recombinant adenovirus-based interferon biotherapeutics in swine) held by The United States of America, as represented by the Secretary of Agriculture expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of Agriculture
Grant date
Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K48/005